Suchergebnisse - "Shieh, Perry B"

PubPharm (116)

31

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

32

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

33

Safety and efficacy of nusinersen in spinal muscular atrophy : The EMBRACE study

enthalten in: Muscle & nerve | 2021

von Acsadi, G. | Crawford, T. | Müller-Felber, W. | +8

34

Genotype-phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders

enthalten in: Genome medicine | 2021

von Mannucci, I. | Dang, N. | Huber, H. | +62

35

Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders

enthalten in: Genome medicine | 2021

von Mannucci, I. | Dang, N. | Huber, H. | +62

36

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy : Results of the MoveDMD phase 2 and open label extension trial

enthalten in: Neuromuscular disorders : NMD | 2021

von Finkel, R. | Finanger, E. | Vandenborne, K. | +15

37

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE) : an open-label, single-arm, multicentre, phase 3 trial

enthalten in: The Lancet. Neurology | 2021

von Day, J. | Finkel, R. | Chiriboga, C. | +18

CommentIn: Lancet Neurol. 2021 Apr;20(4):251-252. - PMID 33743228

38

Reldesemtiv in Patients with Spinal Muscular Atrophy : a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

ErratumIn: Neurotherapeutics. 2021 Jul;18(3):2130. - PMID 34731415

39

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

40

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20